Contact Us

    USA

    • 45-1 Ramsey Road, Shirley, NY 11967, USA
    • 1-631-466-5530

    Europe

    • Heidenkampsweg 58, 20097 Hamburg, Germany
    • 44-207-097-1828

Specific Oncolytic Viruses

Oncolytic Virus Therapy

The oncolytic virus is not a specific virus, but a type of virus that tends to infect tumor cells and can proliferate in large numbers in the tumor cells, eventually causing the tumor cells to lyse, break down, and die. The progeny virus particles released from the lysed tumor cells can further infect the surrounding tumor cells. Tumor treatment using this virus is called oncolytic virus therapy. Oncolytic virus therapy uses a virus that selectively infects and damages tumor tissue without causing damage to normal tissue. Oncolytic viruses can be engineered or screened to selectively expand and kill cancer cells. Oncolytic viruses can infect or metastasize in human systems or in situ, so they can play a role in situ and migrating tumor sites. A general design principle of the oncolytic virus therapy targeting strategy is to delete the virus's toxic factor genes, by applying aberrant signaling pathways in cancer cells to prevent them from replicating in normal cells, while maintaining replication and killing vitality in cancer cells.

Types of Oncolytic Viruses

According to the genetic material of the oncolytic virus, it is divided into DNA and RNA viruses. Many types of oncolytic viruses, including adenovirus, reovirus, measles virus, herpes simplex virus and vaccinia virus, have been used as oncolytic agents in clinical trials. Whereas, the research on oncolytic adenovirus and oncolytic herpes virus is the most in-depth. Most of the oncolytic viruses under study are genetically modified for tumor selection, although there are also cases of using natural wild-type oncolytic viruses in clinical trials.

Based on the OncoVirapy™ platform, Creative Biolabs provides customized, standardized, reliable and high-quality oncolytic virus therapy development services for clients worldwide regarding oncolytic virus engineering, cell biology, animal testing, in vitro validation and in vivo preclinical study. Currently, we are experienced in developing oncolytic virus therapy using various viruses described as follows:

Features of Selected DNA Oncolytic Viruses


Herpes Simplex Virus Adenovirus Vaccinia Virus Parvovirus
Family Herpesviridae Adenoviridae Poxviridae Parvoviridae
Genome dsDNA dsDNA dsDNA ssDNA
Method of entry HVEM, nectin 1 or 2 CAR Macropinocytosis Sialic acid residues
Disease types for clinical trials melanoma, head and neck cancer, pancreatic cancer, GBM, breast cancer, HCC head and neck cancer, pancreatic cancer, GBM, breast cancer, prostate cancer, ovarian cancer, CRC, bladder cancer head and neck cancer, melanoma, lung cancer, breast cancer, HCC, CRC GBM

Features of Selected RNA Oncolytic Viruses


Reovirus Coxsackievirus Poliovirus Seneca Valley Virus Measles Virus Newcastle Disease Virus Vesicular Stomatitis Virus Maraba Virus Orthoreovirus Semliki Forest Virus Sindbis Virus
Family Reoviridae Picornaviridae Picornaviridae Picornaviridae Paramyxoviridae Paramyxoviridae Paramyxoviridae Rhabdoviridae Reoviridae Togaviridae Togaviridae
Genome dsRNA (+)ssRNA (-)ssRNA (+)ssRNA (-)ssRNA (-)ssRNA (-)ssRNA (-)ssRNA dsRNA (+)ssRNA (+)ssRNA
Method of entry JAM-A CAR/ICAM1/DAF CD155 Endocytosis SLAM, CD46 Endocytosis, direct fusion LDLR - Receptor-mediated endocytosis Clathrin-mediated endocytosis Laminin receptor
Disease types for clinical trials head and neck cancer, pancreatic cancer, melanoma, ovarian cancer, NSCLC, CRC, glioma, sarcoma melanoma, bladder cancer, prostate cancer, breast cancer GBM neuroendocrine tumors, lung cancer, neuroblastoma multiple myeloma, ovarian cancer, GBM, oral cancer, peritoneal malignancies GBM HCC metastatic melanoma, squamous cell skin carcinoma multiple myeloma, ovarian epithelial, and pancreatic cancers pre-clinically tested against glioblastoma pre-clinical

By applying a variety of vaccine development strategies, Creative Biolabs is well prepared to aid customs in developing kinds of oncolytic virus-based therapies.

Please feel free to contact us for a quote and further discussion with our scientists.

All services and products are for lab research only, not for any clinical use.

Online Inquiry

  • Verification code
    Click image to refresh the verification code.

Contact Us

  • USA
  • 45-1 Ramsey Road, Shirley, NY 11967, USA
  • Tel: 1-631-466-5530
  • Fax: 1-631-207-8356
  • Email:

Contact Us

  • Europe
  • Heidenkampsweg 58, 20097 Hamburg, Germany
  • Tel: 44-207-097-1828
  • Email:

Copyright © 2007 - 2020 Creative Biolabs. All Rights Reserved